Advertisement

Vaccines in Humoral Primary Immunodeficiencies

  • Lorenzo Lodi
  • Maurizio de Martino
Chapter
Part of the Rare Diseases of the Immune System book series (RDIS)

Abstract

Vaccines in humoral immunodeficiencies play a pivotal role both in prevention and diagnosis. Due to the generally severe course of infections and to the poor response to conventional antimicrobial treatments, individual prevention through vaccination, as well as protection through herd immunity, is crucial in this population. However, some fundamental issues regarding safety and efficacy have to be stressed. In particular, focus should be put on the increased hazard of vaccine-induced infection, on the potentially lower immunogenicity, and on the susceptibility to specific pathogens.

The aim of this chapter is to offer a general approach both to prophylactic and diagnostic vaccination in patients with humoral immunodeficiencies based on literature review and practical experience. In recent years we are witnessing the rapid identification of new diseases and causative genes. For this reason, it is the aim of the authors to offer general principles that could be applicable also into newly discovered clinical entities instead of focusing on specific defects. Specific recommendations will be made only regarding well-defined and studied conditions. Viable and nonviable vaccines will be analyzed separately as well as vaccination in defined patient groups (e.g., patients receiving immunoglobulin, immunomodulatory drugs or transplant, household contacts, travelers, and pregnant women).

Besides their prophylactic use, vaccination also plays a pivotal role as diagnostic tool in humoral immunodeficiencies; a practical approach to the evaluation of specific antibody production will be briefly presented at the end of this chapter.

Keywords

Vaccine Vaccination Humoral Primary immunodeficiency 

References

  1. 1.
    Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136:1186–1205.e1-78.CrossRefGoogle Scholar
  2. 2.
    Eibl MM, Wolf HM. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015;7:1273–92.CrossRefGoogle Scholar
  3. 3.
    Pinkbook|Immunization Strategies|Epidemiology of VPDs|CDC. https://www.cdc.gov/vaccines/pubs/pinkbook/strat.html. Accessed 21 Oct 2017.
  4. 4.
    Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35:696–726.CrossRefGoogle Scholar
  5. 5.
    American Academy of Pediatrics, Committee on Infectious Diseases; Kimberlin DW, Brady MT, Jackson MA, Long SS (2015) Red book: 2015 report of the Committee on infectious diseases.Google Scholar
  6. 6.
    Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133:961–6.CrossRefGoogle Scholar
  7. 7.
    Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:1066–75.CrossRefGoogle Scholar
  8. 8.
    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;58:e44–100.CrossRefGoogle Scholar
  9. 9.
    (2017) Pinkbook|Schedules and Recommendations|Epidemiology of Vaccine Preventable Diseases|CDC. https://www.cdc.gov/vaccines/pubs/pinkbook/appendix/appdx-a.html. Accessed 23 Oct 2017.
  10. 10.
    Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33:1235–42.CrossRefGoogle Scholar
  11. 11.
    Research C for BE and Approved Products—October 20, 2014 Approval Letter—Adenovirus Type 4 and Type 7 Vaccine, Live, Oral. https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm419764.htm. Accessed 6 Oct 2017.
  12. 12.
    Yazdani R, Azizi G, Abolhassani H, Aghamohammadi A. Selective IgA deficiency: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. Scand J Immunol. 2017;85:3–12.CrossRefGoogle Scholar
  13. 13.
    Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine. 2014;32:3725–31.CrossRefGoogle Scholar
  14. 14.
    Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh M, Parvaneh N, Abolhassani H, Pourpak Z, Moin M. IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol. 2009;29:130–6.CrossRefGoogle Scholar
  15. 15.
    Diseases AC on. Red Book. 29th ed. Elk Grove Village: American Academy of Pediatrics; 2012.Google Scholar
  16. 16.
    Moylett EH, Wasan AN, Noroski LM, Shearer WT. Live viral vaccines in patients with partial DiGeorge syndrome: clinical experience and cellular immunity. Clin Immunol Orlando Fla. 2004;112:106–12.CrossRefGoogle Scholar
  17. 17.
    Al-Sukaiti N, Reid B, Lavi S, Al-Zaharani D, Atkinson A, Roifman CM, Grunebaum E. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. J Allergy Clin Immunol. 2010;126:868–9.CrossRefGoogle Scholar
  18. 18.
    Hofstetter AM, Jakob K, Klein NP, Dekker CL, Edwards KM, Halsey NA, Baxter R, Williams SE, Graham PL, LaRussa P. Live vaccine use and safety in DiGeorge syndrome. Pediatrics. 2014;133:e946–54.CrossRefGoogle Scholar
  19. 19.
    Centers for Disease Control (CDC). Guidelines for prophylaxis against Pneumocystis Carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Suppl. 1989;38:1–9.Google Scholar
  20. 20.
    Addition of Severe Combined Immunodeficiency as a Contraindication for Administration of Rotavirus Vaccine. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5922a3.htm. Accessed 19 Oct 2017.
  21. 21.
    Prevention of Rotavirus Gastroenteritis Among Infants and Children Recommendations of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5802a1.htm. Accessed 19 Oct 2017.
  22. 22.
    Siber GR, Werner BG, Halsey NA, Reid R, Almeido-Hill J, Garrett SC, Thompson C, Santosham M. Interference of immune globulin with measles and rubella immunization. J Pediatr. 1993;122:204–11.CrossRefGoogle Scholar
  23. 23.
    Beck CR, BC MK, Hashim AB, Harris RC, University of Nottingham Influenza and the Immuno Compromised (UNIIC) Study Group, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012;206:1250–9.CrossRefGoogle Scholar
  24. 24.
    Muller RB, Maier R, Hoschler K, Zambon M, Ludewig B, Herrmann M, Schulze-Koops H, von Kempis J. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. Clin Exp Rheumatol. 2013;31:723–30.PubMedGoogle Scholar
  25. 25.
    Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67:937–41.CrossRefGoogle Scholar
  26. 26.
    Committee on Infectious Diseases. HPV vaccine recommendations. Pediatrics. 2012;129:602–5.CrossRefGoogle Scholar
  27. 27.
    Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA, Unger ER, Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1–30.PubMedGoogle Scholar
  28. 28.
    Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR Recomm Rep. 2000;49:1–20.Google Scholar
  29. 29.
    Centers for Disease Control and Prevention. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies-recommendations of the Advisory Committee on Immunization Practice. Ann Emerg Med. 2010;56:64–7.CrossRefGoogle Scholar
  30. 30.
    Plebani A, Fischer MB, Meini A, Duse M, Thon V, Eibl MM. T cell activity and cytokine production in X-linked agammaglobulinemia: implications for vaccination strategies. Int Arch Allergy Immunol. 1997;114:90–3.CrossRefGoogle Scholar
  31. 31.
    Paroli M, Accapezzato D, Francavilla V, Insalaco A, Plebani A, Balsano F, Barnaba V. Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia. Blood. 2002;99:2131–7.CrossRefGoogle Scholar
  32. 32.
    Amedei A, Romagnani C, Benagiano M, Azzurri A, Fomia F, Torrente F, Plebani A, D’Elios MM, Del Prete G. Preferential Th1 profile of T helper cell responses in X-linked (Bruton’s) agammaglobulinemia. Eur J Immunol. 2001;31:1927–34.CrossRefGoogle Scholar
  33. 33.
    Barbaro M, Ohlsson A, Borte S, Jonsson S, Zetterström RH, King J, Winiarski J, von Döbeln U, Hammarström L. Newborn screening for severe primary immunodeficiency diseases in Sweden—a 2-year Pilot TREC and KREC screening study. J Clin Immunol. 2017;37:51–60.CrossRefGoogle Scholar
  34. 34.
    Lodi L, Ricci S, Romano F, Ghiori F, Canessa C, Lippi F, Bianchi L, Azzari C. Newborn screening for PIDs using both TREC and KREC identifies late occurrence of B cells. Pediatr Allergy Immunol. 2017;28:498–500.CrossRefGoogle Scholar
  35. 35.
    Mieves JF, Wittke K, Freitag H, Volk H-D, Scheibenbogen C, Hanitsch LG. Influenza vaccination in patients with common variable immunodeficiency (CVID). Curr Allergy Asthma Rep. 2017;17:78.CrossRefGoogle Scholar
  36. 36.
    Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J, Eibel H, Schlesier M, Peter HH. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol Orlando Fla. 2007;124:294–303.CrossRefGoogle Scholar
  37. 37.
    Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38–59.CrossRefGoogle Scholar
  38. 38.
    Adam E, Church JA. Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy. J Clin Immunol. 2015;35:213–7.CrossRefGoogle Scholar
  39. 39.
    Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun. 2001;16:309–18.CrossRefGoogle Scholar
  40. 40.
    Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep. 2015;  https://doi.org/10.1007/s11926-015-0519-y.
  41. 41.
    Handisurya A, Schellenbacher C, Reininger B, Koszik F, Vyhnanek P, Heitger A, Kirnbauer R, Förster-Waldl E. A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. Vaccine. 2010;28:4837–41.CrossRefGoogle Scholar
  42. 42.
    Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE, Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, Coustan-Smith E, Howard V, Campana D. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199–227.CrossRefGoogle Scholar
  44. 44.
    Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm#Tab12. Accessed 18 Oct 2017.
  45. 45.
    Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children Aged 6–18 years with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6225a3.htm. Accessed 18 Oct 2017.
  46. 46.
    Zielen S, Bühring I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun. 2000;68:1435–40.CrossRefGoogle Scholar
  47. 47.
    Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2013. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6324a2.htm. Accessed 18 Oct 2017.
  48. 48.
    Vaccine Schedule. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx. Accessed 31 Oct 2017.
  49. 49.
  50. 50.
    Pinkbook|Meningococcal|Epidemiology of Vaccine Preventable Diseases|CDC. https://www.cdc.gov/vaccines/pubs/pinkbook/mening.html#vaccines. Accessed 18 Oct 2017.
  51. 51.
    Pinkbook|General Recommendations|Epidemiology of VPDs|CDC. https://www.cdc.gov/vaccines/pubs/pinkbook/genrec.html. Accessed 23 Oct 2017.
  52. 52.
    Kaplan JE, Nelson DB, Schonberger LB, Hatch MH, Monath TP, Lazuick JS, Calisher CH, Rosa FW. The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ. 1984;62:585–90.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Glück T, Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46:1459–65.CrossRefGoogle Scholar
  54. 54.
    2018 Yellow Book Home|Travelers’ Health|CDC. https://wwwnc.cdc.gov/travel/page/yellowbook-home. Accessed 2 Nov 2017.
  55. 55.
    Cholera vaccines: WHO position paper—August 2017. Releve Epidemiol Hebd. 2017;92:477–98.Google Scholar
  56. 56.
    Cholera—Chapter 3-2018 Yellow Book|Travelers’ Health|CDC. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/cholera. Accessed 28 Nov 2017.
  57. 57.
    Perry RT, Plowe CV, Koumaré B, Bougoudogo F, Kotloff KL, Losonsky GA, Wasserman SS, Levine MM. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ. 1998;76:63–71.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol. 2002;109:581–91.CrossRefGoogle Scholar
  59. 59.
    Howard V, Myers LA, Williams DA, Wheeler G, Turner EV, Cunningham JM, Conley ME. Stem cell transplants for patients with X-linked agammaglobulinemia. Clin Immunol Orlando Fla. 2003;107:98–102.CrossRefGoogle Scholar
  60. 60.
    Wehr C, Gennery AR, Lindemans C, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015;135:988–97. e6CrossRefGoogle Scholar
  61. 61.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young J-AH, Boeckh MA. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.CrossRefGoogle Scholar
  62. 62.
    (2017) ACIP Altered Immunocompetence Guidelines for Immunizations|Recommendations|CDC. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html. Accessed 7 Nov 2017.
  63. 63.
    Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy Asthma & Immunology. J Allergy Clin Immunol. 2012;130:S1–24.CrossRefGoogle Scholar
  64. 64.
    Shrimpton A, Duddridge M, Ziegler-Heitbrock L. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency. Vaccine. 2006;24:3574–80.CrossRefGoogle Scholar
  65. 65.
    Smith LL, Buckley R, Lugar P. Diagnostic immunization with bacteriophage ΦX 174 in patients with common variable immunodeficiency/hypogammaglobulinemia. Front Immunol. 2014;5:410.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Seidel MG, Planitzer CB, Kreil TR, Förster-Waldl E. Tick-borne encephalitis virus vaccine as additional alternative neoantigen for the clinical immunologist’s toolbox. J Allergy Clin Immunol. 2013;131:617.CrossRefGoogle Scholar
  67. 67.
    Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–65.CrossRefGoogle Scholar
  68. 68.
    McQuillan GM, Kruszon-Moran D, Deforest A, Chu SY, Wharton M. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med. 2002;136:660–6.CrossRefGoogle Scholar
  69. 69.
    Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. 2007;99:462–4.CrossRefGoogle Scholar
  70. 70.
    Leinonen M, Säkkinen A, Kalliokoski R, Luotonen J, Timonen M, Mäkelä PH. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis. 1986;5:39–44.CrossRefGoogle Scholar
  71. 71.
    O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7:597–606.CrossRefGoogle Scholar
  72. 72.
    Fong SW, Qaqundah BY, Taylor WF. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion (Paris). 1974;14:551–9.CrossRefGoogle Scholar
  73. 73.
    Sorensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC, Sacerdote DM, Bradford N, Moore C. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J. 1998;17:685–91.CrossRefGoogle Scholar
  74. 74.
    Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis. 1998;178:870–4.CrossRefGoogle Scholar
  75. 75.
    de Roux A, Schmöle-Thoma B, Schmöele-Thoma B, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015–23.CrossRefGoogle Scholar
  76. 76.
    Hare ND, Smith BJ, Ballas ZK. Antibody response to pneumococcal vaccination as a function of preimmunization titer. J Allergy Clin Immunol. 2009;123:195–200.CrossRefGoogle Scholar
  77. 77.
    Sorensen RU, Leiva LE, Javier FC, Sacerdote DM, Bradford N, Butler B, Giangrosso PA, Moore C. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998;102:215–21.CrossRefGoogle Scholar
  78. 78.
    Fine P, Eames K, Heymann DL. “Herd Immunity”: A Rough Guide. Clin Infect Dis. 2011;52:911–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Post-Graduate School of PediatricsUniversity of FlorenceFlorenceItaly
  2. 2.Pediatric Clinic 1, Anna Meyer University CampusAnna Meyer Children’s University Hospital, University of FlorenceFlorenceItaly

Personalised recommendations